APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gene Therapy on Neurological Diseases

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Gene Therapy on Neurological Diseases Market Analysis and Forecast 2026-2032

2 January 2026190 pages

Choose your research edition.

Industry ResearchGene Therapy on Neurological Diseases Industry Research Report 2026103 pages · $2,950 USDIndustry Growth & TrendsGlobal Gene Therapy on Neurological Diseases Industry Growth and Trends Forecast to 203262 pages · $3,450 USDMarket StructureGlobal Gene Therapy on Neurological Diseases Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032173 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gene Therapy on Neurological Diseases Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Gene Therapy on Neurological Diseases Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Gene Therapy on Neurological Diseases market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Gene Therapy on Neurological Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Gene Therapy on Neurological Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Gene Therapy on Neurological Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Gene Therapy on Neurological Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Gene Therapy on Neurological Diseases include Novartis, Biogen and Sarepta Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Gene Therapy on Neurological Diseases, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Gene Therapy on Neurological Diseases, also provides the revenue of main regions and countries. Of the upcoming market potential for Gene Therapy on Neurological Diseases, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gene Therapy on Neurological Diseases revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Gene Therapy on Neurological Diseases market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Gene Therapy on Neurological Diseases revenue, projected growth trends, production technology, application and end-user industry.

Gene Therapy on Neurological Diseases Segment by Company

Novartis

Biogen

Sarepta Therapeutics

Gene Therapy on Neurological Diseases Segment by Type

Viral Gene Therapy

Non-viral Gene Therapy

Gene Therapy on Neurological Diseases Segment by Application

Hospital

Clinic

Other

Gene Therapy on Neurological Diseases Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapy on Neurological Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gene Therapy on Neurological Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapy on Neurological Diseases.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Gene Therapy on Neurological Diseases in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Gene Therapy on Neurological Diseases company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gene Therapy on Neurological Diseases revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Gene Therapy on Neurological Diseases Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Viral Gene Therapy Major Player Table 3. Non-viral Gene Therapy Major Player Table 4. Global Gene Therapy on Neurological Diseases Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Clinic Major Player Table 7. Other Major Player Table 8. Gene Therapy on Neurological Diseases Industry Trends Table 9. Gene Therapy on Neurological Diseases Industry Drivers Table 10. Gene Therapy on Neurological Diseases Industry Opportunities and Challenges Table 11. Gene Therapy on Neurological Diseases Industry Restraints Table 12. Global Gene Therapy on Neurological Diseases Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Gene Therapy on Neurological Diseases Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Gene Therapy on Neurological Diseases Market Share by Region (2021-2026) Table 15. Global Gene Therapy on Neurological Diseases Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Gene Therapy on Neurological Diseases Market Share by Region (2027-2032) Table 17. Global Gene Therapy on Neurological Diseases Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Gene Therapy on Neurological Diseases Revenue Market Share by Players (2021-2026) Table 19. Global Gene Therapy on Neurological Diseases Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Gene Therapy on Neurological Diseases Key Players Headquarters & Area Served Table 21. Global Gene Therapy on Neurological Diseases Players, Product Type & Application Table 22. Global Gene Therapy on Neurological Diseases Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Gene Therapy on Neurological Diseases by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Gene Therapy on Neurological Diseases Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Gene Therapy on Neurological Diseases Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Gene Therapy on Neurological Diseases Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Gene Therapy on Neurological Diseases Revenue Market Share by Type (2021-2026) Table 29. Global Gene Therapy on Neurological Diseases Revenue Market Share by Type (2027-2032) Table 30. Global Gene Therapy on Neurological Diseases Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Gene Therapy on Neurological Diseases Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Gene Therapy on Neurological Diseases Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Gene Therapy on Neurological Diseases Revenue Market Share by Application (2021-2026) Table 34. Global Gene Therapy on Neurological Diseases Revenue Market Share by Application (2027-2032) Table 35. Novartis Company Information Table 36. Novartis Business Overview Table 37. Novartis Gene Therapy on Neurological Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Novartis Gene Therapy on Neurological Diseases Product Portfolio Table 39. Novartis Recent Development Table 40. Biogen Company Information Table 41. Biogen Business Overview Table 42. Biogen Gene Therapy on Neurological Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Biogen Gene Therapy on Neurological Diseases Product Portfolio Table 44. Biogen Recent Development Table 45. Sarepta Therapeutics Company Information Table 46. Sarepta Therapeutics Business Overview Table 47. Sarepta Therapeutics Gene Therapy on Neurological Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Sarepta Therapeutics Gene Therapy on Neurological Diseases Product Portfolio Table 49. Sarepta Therapeutics Recent Development Table 50. North America Gene Therapy on Neurological Diseases Revenue by Type (2021-2026) & (US$ Million) Table 51. North America Gene Therapy on Neurological Diseases Revenue by Type (2027-2032) & (US$ Million) Table 52. North America Gene Therapy on Neurological Diseases Revenue by Application (2021-2026) & (US$ Million) Table 53. North America Gene Therapy on Neurological Diseases Revenue by Application (2027-2032) & (US$ Million) Table 54. North America Gene Therapy on Neurological Diseases Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 55. North America Gene Therapy on Neurological Diseases Revenue by Country (2021-2026) & (US$ Million) Table 56. North America Gene Therapy on Neurological Diseases Revenue by Country (US$ Million) & (2027-2032) Table 57. Europe Gene Therapy on Neurological Diseases Revenue by Type (2021-2026) & (US$ Million) Table 58. Europe Gene Therapy on Neurological Diseases Revenue by Type (2027-2032) & (US$ Million) Table 59. Europe Gene Therapy on Neurological Diseases Revenue by Application (2021-2026) & (US$ Million) Table 60. Europe Gene Therapy on Neurological Diseases Revenue by Application (2027-2032) & (US$ Million) Table 61. Europe Gene Therapy on Neurological Diseases Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 62. Europe Gene Therapy on Neurological Diseases Revenue by Country (2021-2026) & (US$ Million) Table 63. Europe Gene Therapy on Neurological Diseases Revenue by Country (US$ Million) & (2027-2032) Table 64. China Gene Therapy on Neurological Diseases Revenue by Type (2021-2026) & (US$ Million) Table 65. China Gene Therapy on Neurological Diseases Revenue by Type (2027-2032) & (US$ Million) Table 66. China Gene Therapy on Neurological Diseases Revenue by Application (2021-2026) & (US$ Million) Table 67. China Gene Therapy on Neurological Diseases Revenue by Application (2027-2032) & (US$ Million) Table 68. Asia Gene Therapy on Neurological Diseases Revenue by Type (2021-2026) & (US$ Million) Table 69. Asia Gene Therapy on Neurological Diseases Revenue by Type (2027-2032) & (US$ Million) Table 70. Asia Gene Therapy on Neurological Diseases Revenue by Application (2021-2026) & (US$ Million) Table 71. Asia Gene Therapy on Neurological Diseases Revenue by Application (2027-2032) & (US$ Million) Table 72. Asia Gene Therapy on Neurological Diseases Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 73. Asia Gene Therapy on Neurological Diseases Revenue by Region (US$ Million) & (2021-2026) Table 74. Asia Gene Therapy on Neurological Diseases Revenue by Region (US$ Million) & (2027-2032) Table 75. SAMEA Gene Therapy on Neurological Diseases Revenue by Type (2021-2026) & (US$ Million) Table 76. SAMEA Gene Therapy on Neurological Diseases Revenue by Type (2027-2032) & (US$ Million) Table 77. SAMEA Gene Therapy on Neurological Diseases Revenue by Application (2021-2026) & (US$ Million) Table 78. SAMEA Gene Therapy on Neurological Diseases Revenue by Application (2027-2032) & (US$ Million) Table 79. SAMEA Gene Therapy on Neurological Diseases Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 80. SAMEA Gene Therapy on Neurological Diseases Revenue by Country (2021-2026) & (US$ Million) Table 81. SAMEA Gene Therapy on Neurological Diseases Revenue by Country (US$ Million) & (2027-2032) Table 82. Research Programs/Design for This Report Table 83. Authors List of This Report Table 84. Secondary Sources Table 85. Primary Sources List of Figures Figure 1. Gene Therapy on Neurological Diseases Image Figure 2. Global Gene Therapy on Neurological Diseases Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gene Therapy on Neurological Diseases Market Size Share 2021 VS 2025 VS 2032 Figure 4. Viral Gene Therapy Image Figure 5. Non-viral Gene Therapy Image Figure 6. Global Gene Therapy on Neurological Diseases Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Gene Therapy on Neurological Diseases Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Other Image Figure 11. Global Gene Therapy on Neurological Diseases Market Size (US$ Million) & (2021-2032) Figure 12. Global Gene Therapy on Neurological Diseases Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Gene Therapy on Neurological Diseases Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Gene Therapy on Neurological Diseases Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Gene Therapy on Neurological Diseases Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Gene Therapy on Neurological Diseases Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Gene Therapy on Neurological Diseases Revenue Market Share by Type (2021-2032) Figure 19. Global Gene Therapy on Neurological Diseases Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Gene Therapy on Neurological Diseases Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Gene Therapy on Neurological Diseases Revenue Market Share by Application (2021-2032) Figure 22. North America Gene Therapy on Neurological Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Gene Therapy on Neurological Diseases Revenue Share by Type (2021-2032) Figure 24. North America Gene Therapy on Neurological Diseases Revenue Share by Application (2021-2032) Figure 25. North America Gene Therapy on Neurological Diseases Revenue Share by Country (2021-2032) Figure 26. United States Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Gene Therapy on Neurological Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Gene Therapy on Neurological Diseases Revenue Share by Type (2021-2032) Figure 31. Europe Gene Therapy on Neurological Diseases Revenue Share by Application (2021-2032) Figure 32. Europe Gene Therapy on Neurological Diseases Revenue Share by Country (2021-2032) Figure 33. Germany Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Gene Therapy on Neurological Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Gene Therapy on Neurological Diseases Revenue Share by Type (2021-2032) Figure 43. China Gene Therapy on Neurological Diseases Revenue Share by Application (2021-2032) Figure 44. Asia Gene Therapy on Neurological Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Gene Therapy on Neurological Diseases Revenue Share by Type (2021-2032) Figure 46. Asia Gene Therapy on Neurological Diseases Revenue Share by Application (2021-2032) Figure 47. Asia Gene Therapy on Neurological Diseases Revenue Share by Region (2021-2032) Figure 48. Japan Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Gene Therapy on Neurological Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Gene Therapy on Neurological Diseases Revenue Share by Type (2021-2032) Figure 56. SAMEA Gene Therapy on Neurological Diseases Revenue Share by Application (2021-2032) Figure 57. SAMEA Gene Therapy on Neurological Diseases Revenue Share by Country (2021-2032) Figure 58. Brazil Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Gene Therapy on Neurological Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Viral Gene Therapy
  • Non-viral Gene Therapy
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Novartis
  • Biogen
  • Sarepta Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Gene Therapy on Neurological Diseases Market by Type
  3. 1.2.1 Global Gene Therapy on Neurological Diseases Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Viral Gene Therapy
  5. 1.2.3 Non-viral Gene Therapy
  6. 1.3 Gene Therapy on Neurological Diseases Market by Application
  7. 1.3.1 Global Gene Therapy on Neurological Diseases Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Gene Therapy on Neurological Diseases Market Dynamics
  1. 2.1 Gene Therapy on Neurological Diseases Industry Trends
  2. 2.2 Gene Therapy on Neurological Diseases Industry Drivers
  3. 2.3 Gene Therapy on Neurological Diseases Industry Opportunities and Challenges
  4. 2.4 Gene Therapy on Neurological Diseases Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Gene Therapy on Neurological Diseases Market Perspective (2021-2032)
  2. 3.2 Global Gene Therapy on Neurological Diseases Growth Trends by Region
  3. 3.2.1 Global Gene Therapy on Neurological Diseases Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Gene Therapy on Neurological Diseases Market Size by Region (2021-2026)
  5. 3.2.3 Global Gene Therapy on Neurological Diseases Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Gene Therapy on Neurological Diseases Revenue by Players
  2. 4.1.1 Global Gene Therapy on Neurological Diseases Revenue by Players (2021-2026)
  3. 4.1.2 Global Gene Therapy on Neurological Diseases Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Gene Therapy on Neurological Diseases Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Gene Therapy on Neurological Diseases Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Gene Therapy on Neurological Diseases Key Players Headquarters & Area Served
  7. 4.4 Global Gene Therapy on Neurological Diseases Players, Product Type & Application
  8. 4.5 Global Gene Therapy on Neurological Diseases Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Gene Therapy on Neurological Diseases Market CR5 and HHI
  11. 4.6.3 2025 Gene Therapy on Neurological Diseases Tier 1, Tier 2, and Tier 3
5 Gene Therapy on Neurological Diseases Market Size by Type
  1. 5.1 Global Gene Therapy on Neurological Diseases Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Gene Therapy on Neurological Diseases Revenue by Type (2021-2032)
  3. 5.3 Global Gene Therapy on Neurological Diseases Revenue Market Share by Type (2021-2032)
6 Gene Therapy on Neurological Diseases Market Size by Application
  1. 6.1 Global Gene Therapy on Neurological Diseases Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Gene Therapy on Neurological Diseases Revenue by Application (2021-2032)
  3. 6.3 Global Gene Therapy on Neurological Diseases Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Gene Therapy on Neurological Diseases Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Gene Therapy on Neurological Diseases Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Biogen
  8. 7.2.1 Biogen Company Information
  9. 7.2.2 Biogen Business Overview
  10. 7.2.3 Biogen Gene Therapy on Neurological Diseases Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Biogen Gene Therapy on Neurological Diseases Product Portfolio
  12. 7.2.5 Biogen Recent Developments
  13. 7.3 Sarepta Therapeutics
  14. 7.3.1 Sarepta Therapeutics Company Information
  15. 7.3.2 Sarepta Therapeutics Business Overview
  16. 7.3.3 Sarepta Therapeutics Gene Therapy on Neurological Diseases Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sarepta Therapeutics Gene Therapy on Neurological Diseases Product Portfolio
  18. 7.3.5 Sarepta Therapeutics Recent Developments
8 North America
  1. 8.1 North America Gene Therapy on Neurological Diseases Revenue (2021-2032)
  2. 8.2 North America Gene Therapy on Neurological Diseases Revenue by Type (2021-2032)
  3. 8.2.1 North America Gene Therapy on Neurological Diseases Revenue by Type (2021-2026)
  4. 8.2.2 North America Gene Therapy on Neurological Diseases Revenue by Type (2027-2032)
  5. 8.3 North America Gene Therapy on Neurological Diseases Revenue Share by Type (2021-2032)
  6. 8.4 North America Gene Therapy on Neurological Diseases Revenue by Application (2021-2032)
  7. 8.4.1 North America Gene Therapy on Neurological Diseases Revenue by Application (2021-2026)
  8. 8.4.2 North America Gene Therapy on Neurological Diseases Revenue by Application (2027-2032)
  9. 8.5 North America Gene Therapy on Neurological Diseases Revenue Share by Application (2021-2032)
  10. 8.6 North America Gene Therapy on Neurological Diseases Revenue by Country
  11. 8.6.1 North America Gene Therapy on Neurological Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Gene Therapy on Neurological Diseases Revenue by Country (2021-2026)
  13. 8.6.3 North America Gene Therapy on Neurological Diseases Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Gene Therapy on Neurological Diseases Revenue (2021-2032)
  2. 9.2 Europe Gene Therapy on Neurological Diseases Revenue by Type (2021-2032)
  3. 9.2.1 Europe Gene Therapy on Neurological Diseases Revenue by Type (2021-2026)
  4. 9.2.2 Europe Gene Therapy on Neurological Diseases Revenue by Type (2027-2032)
  5. 9.3 Europe Gene Therapy on Neurological Diseases Revenue Share by Type (2021-2032)
  6. 9.4 Europe Gene Therapy on Neurological Diseases Revenue by Application (2021-2032)
  7. 9.4.1 Europe Gene Therapy on Neurological Diseases Revenue by Application (2021-2026)
  8. 9.4.2 Europe Gene Therapy on Neurological Diseases Revenue by Application (2027-2032)
  9. 9.5 Europe Gene Therapy on Neurological Diseases Revenue Share by Application (2021-2032)
  10. 9.6 Europe Gene Therapy on Neurological Diseases Revenue by Country
  11. 9.6.1 Europe Gene Therapy on Neurological Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Gene Therapy on Neurological Diseases Revenue by Country (2021-2026)
  13. 9.6.3 Europe Gene Therapy on Neurological Diseases Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Gene Therapy on Neurological Diseases Revenue (2021-2032)
  2. 10.2 China Gene Therapy on Neurological Diseases Revenue by Type (2021-2032)
  3. 10.2.1 China Gene Therapy on Neurological Diseases Revenue by Type (2021-2026)
  4. 10.2.2 China Gene Therapy on Neurological Diseases Revenue by Type (2027-2032)
  5. 10.3 China Gene Therapy on Neurological Diseases Revenue Share by Type (2021-2032)
  6. 10.4 China Gene Therapy on Neurological Diseases Revenue by Application (2021-2032)
  7. 10.4.1 China Gene Therapy on Neurological Diseases Revenue by Application (2021-2026)
  8. 10.4.2 China Gene Therapy on Neurological Diseases Revenue by Application (2027-2032)
  9. 10.5 China Gene Therapy on Neurological Diseases Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Gene Therapy on Neurological Diseases Revenue (2021-2032)
  2. 11.2 Asia Gene Therapy on Neurological Diseases Revenue by Type (2021-2032)
  3. 11.2.1 Asia Gene Therapy on Neurological Diseases Revenue by Type (2021-2026)
  4. 11.2.2 Asia Gene Therapy on Neurological Diseases Revenue by Type (2027-2032)
  5. 11.3 Asia Gene Therapy on Neurological Diseases Revenue Share by Type (2021-2032)
  6. 11.4 Asia Gene Therapy on Neurological Diseases Revenue by Application (2021-2032)
  7. 11.4.1 Asia Gene Therapy on Neurological Diseases Revenue by Application (2021-2026)
  8. 11.4.2 Asia Gene Therapy on Neurological Diseases Revenue by Application (2027-2032)
  9. 11.5 Asia Gene Therapy on Neurological Diseases Revenue Share by Application (2021-2032)
  10. 11.6 Asia Gene Therapy on Neurological Diseases Revenue by Country
  11. 11.6.1 Asia Gene Therapy on Neurological Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Gene Therapy on Neurological Diseases Revenue by Country (2021-2026)
  13. 11.6.3 Asia Gene Therapy on Neurological Diseases Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Gene Therapy on Neurological Diseases Revenue (2021-2032)
  2. 12.2 SAMEA Gene Therapy on Neurological Diseases Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Gene Therapy on Neurological Diseases Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Gene Therapy on Neurological Diseases Revenue by Type (2027-2032)
  5. 12.3 SAMEA Gene Therapy on Neurological Diseases Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Gene Therapy on Neurological Diseases Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Gene Therapy on Neurological Diseases Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Gene Therapy on Neurological Diseases Revenue by Application (2027-2032)
  9. 12.5 SAMEA Gene Therapy on Neurological Diseases Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Gene Therapy on Neurological Diseases Revenue by Country
  11. 12.6.1 SAMEA Gene Therapy on Neurological Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Gene Therapy on Neurological Diseases Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Gene Therapy on Neurological Diseases Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst